NAGPA and Parkinson disease: It is also important to mention the significant upregulation of N-Acetylglucosamine-1-Phosphodiester Alpha-N-Acetylglucosaminidase (NAGPA) (3.52-fold) and B3GNT-2, -8, seen both in the ILBD and PD striatum, which might indicate that the changes in these pathways start from the early stages of the disease.